SCHEDULE: Freedman Boosts Eupraxia Stake to 10.2%

Joseph S. Freedman increased his beneficial ownership in Eupraxia Pharmaceuticals Inc. to 10.2% after purchasing 543,130 common shares in a recent public offering.

Summary

• Joseph S. Freedman, the Reporting Person, acquired an additional 543,130 common shares of Eupraxia Pharmaceuticals Inc. in an underwritten public offering on September 24, 2025.
• The purchase was made at a price of $5.50 per share, totaling $2,987,215, funded by personal funds.
• Following this transaction, Mr. Freedman's aggregate beneficial ownership in Eupraxia Pharmaceuticals Inc. increased to 5,533,215 shares, representing 10.2% of the class.
• The beneficial ownership includes common shares, Series 1 preferred shares, options to purchase common shares, and warrants exercisable for common shares, held directly, jointly, in trust, and by children.
• In connection with the offering, Mr. Freedman entered into a 90-day lock-up agreement, restricting the sale or transfer of his securities without underwriter consent.
• Mr. Freedman also entered into option agreements allowing certain consultants of the Issuer to purchase 60,000 shares of Common Stock beneficially owned by him.

Sentiment

Score: 7

Explanation: The increased stake by a significant individual investor, Joseph S. Freedman, to 10.2% suggests confidence in the company's future. While the lock-up is a minor restriction, the overall sentiment from this filing is positive due to the substantial personal investment.

Positives

• Increased stake by a significant individual investor, Joseph S. Freedman, to 10.2% demonstrates continued confidence in Eupraxia Pharmaceuticals Inc.
• The purchase of 543,130 common shares for $2,987,215 in a public offering indicates a substantial personal investment.

Negatives

• Joseph S. Freedman is subject to a 90-day lock-up agreement, restricting his ability to sell or transfer Eupraxia Pharmaceuticals Inc. securities.

Risks

• The lock-up agreement restricts the Reporting Person's liquidity for 90 days regarding his holdings in Eupraxia Pharmaceuticals Inc.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from the company or the reporting person regarding the company's future performance. It primarily details a past transaction and current holdings.

Industry Context

This filing reflects an individual investor's increased stake in a pharmaceutical company. While not directly addressing broader industry trends, increased insider or significant shareholder investment can signal confidence in the company's prospects within the competitive pharmaceutical sector.

Related Party Transactions

• Joseph S. Freedman entered into option agreements with certain consultants of the Issuer, granting them the option to purchase 60,000 shares of Common Stock beneficially owned by him.

Stakeholder Impact

• Shareholders: The increased stake by a significant investor may be viewed positively, signaling confidence. The lock-up agreement temporarily reduces potential selling pressure from this large holder.
• Consultants: Certain consultants of the Issuer have been granted options to purchase shares from Joseph S. Freedman, potentially aligning their interests with the company's performance.

Next Steps

• The 90-day lock-up period for Joseph S. Freedman's securities will expire, after which he will be free to sell or transfer shares, subject to market conditions and regulatory compliance.
• The consultants holding options to purchase 60,000 shares from Mr. Freedman may choose to exercise these options.

Key Dates

Recommendation

The filing indicates a significant insider purchase by Joseph S. Freedman, increasing his beneficial ownership to 10.2%. This demonstrates strong confidence from a key individual. However, the filing is an ownership disclosure and does not provide new operational or financial performance data for Eupraxia Pharmaceuticals Inc. to warrant a 'buy' or 'sell' recommendation. The lock-up agreement is a neutral factor. Therefore, a 'hold' recommendation is appropriate, awaiting further company-specific performance updates.

Keywords

Eupraxia Pharmaceuticals, Joseph S. Freedman, Schedule 13D, Share Purchase, Beneficial Ownership, Public Offering, Lock-Up Agreement, Common Shares, Preferred Shares, Options, Warrants, Biotechnology, Pharmaceuticals